Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 12/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27577278 | 1.00 | EPHX1 (0.63) | EPHX1ACHENAAAFAAHTSHR | |
| SCHEMBL21059108 | 0.98 | EPHX1 (0.60) | EPHX1ACHENAAAFAAH | |
| SCHEMBL11100479 | 0.92 | EPHX1 (0.52) | EPHX1ACHETSHR | |
| Ammonia Solution, Strong SCHEMBL27626603 | 0.90 | EPHX1 (0.50) | EPHX1ACHETSHR | |
| SCHEMBL28042098 | 0.85 | ACHE (0.54) | EPHX1ACHE | |
| SCHEMBL28212419 | 0.85 | ACHE (0.54) | EPHX1ACHE | |
| SCHEMBL21016721 | 0.84 | ACHE (0.42) | EPHX1ACHE | |
| SCHEMBL28164500 | 0.83 | EPHX1 (0.45) | EPHX1ACHEFAAH | |
| SCHEMBL21596988 | 0.83 | EPHX1 (0.43) | EPHX1ACHEFAAH | |
| SCHEMBL27684736 | 0.83 | EPHX1 (0.43) | EPHX1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101597286-A | A kind of organic catalyst and preparation thereof that contains primary amine, tertiary amine and urea or thiocarbamide | DALIAN CHEMICAL PHYSICS INST (CN) | 2009-12-09 | — | — | CN | claimed |
| EP-3508473-B1 | METHOD FOR PRODUCING CARBAMIC ACID ESTER | AIST (JP) | 2021-05-26 | — | — | EP | disclosed |
| US-10752579-B2 | Production method of carbamic acid ester | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2020-08-25 | — | — | US | disclosed |
| CN-110115365-A | The adjusting that actinism receptor and relative ligand are carried out | 西诺米克斯公司 | 2019-08-13 | — | — | CN | disclosed |
| CN-110062753-A | Antiviral compounds | 哈普洛根有限责任公司 | 2019-07-26 | — | — | CN | disclosed |
| EP-3508473-A1 | METHOD FOR PRODUCING CARBAMIC ACID ESTER | National Institute of Advanced Industrial Science and Technology (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20190185420-A1 | PRODUCTION METHOD OF CARBAMIC ACID ESTER | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2019-06-20 | — | — | US | disclosed |
| CN-105452238-A | Bicyclic derivatives containing a pyrimidine ring and process for preparing the same | YUHAN CORP | 2016-03-30 | — | — | CN | disclosed |
| CN-104159891-A | Pyridazine amide compounds and their use as SYK inhibitors | HOFFMANN LA ROCHE | 2014-11-19 | — | — | CN | disclosed |
| CN-103153096-A | Methods of improving the stability of sweetness enhancers and compositions comprising stable sweetness enhancers | SENOMYX INC | 2013-06-12 | — | — | CN | disclosed |
| CN-102958935-A | Macrocyclic integrase inhibitors | TIBOTEC PHARM LTD | 2013-03-06 | — | — | CN | disclosed |
| CN-102300462-A | Inhibitors Of Hcv Ns5a | — | 2011-12-28 | — | — | CN | disclosed |
| CN-102227412-A | Fungicide hydroxyimino-heterocyclic derivatives | BAYER CROPSCIENCE AG | 2011-10-26 | — | — | CN | disclosed |
| CN-102216308-A | [4- (1-amino-ethyl) -cyclohexyl] -methyl-amines as antibacterials | ASTRAZENECA AB | 2011-10-12 | — | — | CN | disclosed |
| CN-102015717-A | Chemokine receptor modulators | ALTIRIS THERAPEUTICS | 2011-04-13 | — | — | CN | disclosed |
| CN-101779124-A | modulation of chemosensory receptors and ligands associated therewith | SENOMYX INC | 2010-07-14 | — | — | CN | disclosed |
| CN-101597286-A | A kind of organic catalyst and preparation thereof that contains primary amine, tertiary amine and urea or thiocarbamide | DALIAN CHEMICAL PHYSICS INST (CN) | 2009-12-09 | — | — | CN | disclosed |
| CN-101534904-A | BCL inhibitors for the treatment of platelet excess | ABBOTT LAB (US) | 2009-09-16 | — | — | CN | disclosed |
| CN-101171230-A | Heterocyclic-substituted alkanamides useful as renin inhibitors | SPEEDEL EXPERIMENTA AG (CH) | 2008-04-30 | — | — | CN | disclosed |
| CN-1348442-A | Novel sulfonamide compounds and uses thereof | MERCK & CO INC (US) | 2002-05-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185420-A1 | PRODUCTION METHOD OF CARBAMIC ACID ESTER | CA2, CA7, CA4 | EPHX1 4759/4885ACHE 195/4885NAAA 15/4885 |
| US-10752579-B2 | Production method of carbamic acid ester | CA2, CA7, CA4 | EPHX1 4759/4885ACHE 195/4885NAAA 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.